Depot-medroxyprogesterone versus norethisterone enantate for long-acting progestogenic contraception

RHL practical aspects by Gray A

FIRST CONTACT (PRIMARY CARE LEVEL)

The decision regarding which of these two long-acting methods would be provided in the national family planning programme would be usually taken at the central level of the health-care system. However, if both depot-medroxyprogesterone acetate (DMPA) and norethisterone enantate (NET-EN) are provided, accurate information about their relative merits and the costs involved must be made available to both health-care providers and clients.

REFERRAL HOSPITAL (SECONDARY CARE) LEVEL

Not applicable.

AT HOME OR IN THE COMMUNITY

Not applicable.


This document should be cited as: Gray A. Depot medroxyprogesterone versus Norethisterone oenanthate for long-acting progestogenic contraception: RHL practical aspects (last revised: 15 December 2006). The WHO Reproductive Health Library; Geneva: World Health Organization.

Share

Related documents

About the author